OS Therapies Incorporated Common Stock (OSTX)
Stock · AMEX · Health Care
$1.64as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$1.47
Industry
Biotechnology: Pharmaceutical Preparations
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- ostherapies.com/
Fundamentals
- 1-day range
- $1.6$1.69
- Market cap
- $74.23M
- P/E (trailing)
- —
- P/E (forward)
- 5.07
- EPS (trailing)
- $-1.05
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 609.6K
52-week range
$1.15$2.54
Next earnings: November 16, 2026 · EPS estimate $-0.10
Forecasts
5 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$13
+692.7%
Median
$8
+387.8%
Low
$6
+265.9%
OS Therapies Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- OSTXOS Therapies Incorporated Common Stock$1.64▼ 2.38%Market cap $74.23MP/E —$1.15$2.54
- ACETAdicet Bio Inc. Common Stock$9.05▲ 0.44%Market cap $74.13MP/E —$6.01$17.44
- SPROSpero Therapeutics Inc. Common Stock$1.2▼ 0.83%Market cap $73.53MP/E 4.73$1.08$3.08
- NMADNomad Power Solutions Inc. Common Stock$4.33▼ 2.04%Market cap $75.50MP/E —$3.12$7.7
- GANXGain Therapeutics Inc. Common Stock$1.78▼ 3.78%Market cap $75.92MP/E —$1.53$4.34
- ACRVAcrivon Therapeutics Inc. Common Stock$2.06▼ 4.19%Market cap $72.33MP/E —$1.27$3.56
- ELTXElicio Therapeutics Inc. Common Stock$2.86▼ 4.67%Market cap $72.28MP/E —$2.66$16
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OSTX OS Therapies Incorporated Common Stock | $74.23M | — | $1.64 | ▼ 2.38% | $1.15$2.54 |
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $9.05 | ▲ 0.44% | $6.01$17.44 |
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 4.73 | $1.2 | ▼ 0.83% | $1.08$3.08 |
| NMAD Nomad Power Solutions Inc. Common Stock | $75.50M | — | $4.33 | ▼ 2.04% | $3.12$7.7 |
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.78 | ▼ 3.78% | $1.53$4.34 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $2.06 | ▼ 4.19% | $1.27$3.56 |
| ELTX Elicio Therapeutics Inc. Common Stock | $72.28M | — | $2.86 | ▼ 4.67% | $2.66$16 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferiesbenzinga · 8/21/2026
- OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through JefferiesBenzinga · 8/21/2026
- OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory UpdatesYahoo · 8/17/2026
- OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic OsteosarcomaYahoo · 8/13/2026
- FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-SeptemberBenzinga · 8/13/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 2.76M
- Total value held
- $3.84M
- Institutional holders
- 27
Top holders this quarter
- Unknown469.5K
- Unknown448.7K
- Unknown400.0K
- Unknown348.7K
- Unknown280.0K
- Unknown245.4K
- Unknown91.2K
- Unknown66.1K
- Unknown64.8K
- Unknown62.5K
See the full, filterable feed with live charts on the MarketWall dashboard.